Table 2.
Eribulin treatment status
| Alla) | First-line | Second-line | Third or later-line | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n = 637 | n = 142 | n = 177 | n = 317 | ||||||
| Start dose (mg/m2), n (%) | 1.4 | 504 | (79.1) | 125 | (88.0) | 140 | (79.1) | 238 | (75.1) |
| 1.1 | 91 | (14.3) | 12 | (8.5) | 27 | (15.3) | 52 | (16.4) | |
| 0.7 | 11 | (1.7) | 2 | (1.4) | 1 | (0.6) | 8 | (2.5) | |
| Other | 31 | (4.9) | 3 | (2.1) | 9 | (5.1) | 19 | (6.0) | |
| Number of cycles | Mean ± SD | 7.7 ± 6.8 | 9.2 ± 8.0 | 8.0 ± 7.3 | 6.8 ± 5.8 | ||||
| Median (min–max) | 5.0 | (1–36) | 6.5 | (1–34) | 6.0 | (1–36) | 5.0 | (1–35) | |
| Dose intensity (mg/m2/week) | Mean ± SD | 0.68 ± 0.18 | 0.73 ± 0.17 | 0.69 ± 0.17 | 0.66 ± 0.18 | ||||
| Median (min–max) | 0.69 | (0.2–0.9) | 0.76 | (0.3–0.9) | 0.7 | (0.2–0.9) | 0.66 | (0.2–0.9) | |
| Relative dose intensity | Mean ± SD | 0.73 ± 0.19 | 0.78 ± 0.19 | 0.73 ± 0.19 | 0.70 ± 0.20 | ||||
| Median (min–max) | 0.74 | (0.2–1.0) | 0.82 | (0.3–1.0) | 0.74 | (0.2–1.0) | 0.71 | (0.2–1.0) | |
max maximum, min minimum, SD standard deviation
a)One patient whose number of previous chemotherapy regimens was unknown was included in the analysis